Gilteritinib, Gilteritinib Hemifumarate, FLT3, AXL, ASP 2215, ASP 2215 Hemifumarate, ASP2215, ASP-2215, ASP2215 Hemifumarate, ASP2215 hemifumarate, ASP-2215 Hemifumarate, TAM Receptor, TAMReceptor
Gilteritinib hemifumarate (ASP2215 hemifumarate) is a highly potent, ATP-competitive dual inhibitor targeting FLT3 and AXL kinases, with IC50 values of 0.29 nM and 0.73 nM, respectively. It is a key research compound for studying relapsed or refractory FLT3-mutant acute myeloid leukemia (AML), utilized in both in vitro cellular assays and in vivo xenograft models to investigate therapeutic mechanisms and resistance.
